Image2_NVP-BEZ235 Inhibits Renal Cell Carcinoma by Targeting TAK1 and PI3K/Akt/mTOR Pathways.JPEG
In spite of the promising in vitro and preclinical results, dual PI3K/Akt/mTOR inhibitor NVP-BEZ235, and ATP-competitive mTOR inhibitor PP242 both failed to confirm their inhibitory efficacy against renal cell carcinoma (RCC) in clinical settings. Therefore, a better understanding of the molecular mechanism is essential so as to provide possibilities for their use in combination with other agents. In present study, RCC cell lines (UMRC6, 786-0 and UOK121) were treated with NVP-BEZ235, PP242 or Rapamycin, an mTOR complex 1 (mTORC1)-specific inhibitor. They all suppressed cell proliferation and invasion, induced apoptosis and cell cycle arrest, and the effects were in the order of NVP-BEZ235 > PP242 > Rapamycin. Accordingly, the marked and sustained decrease in speckle-type POZ protein (SPOP) expression and phosphorylation of Akt and mTOR kinases was observed in RCC cells treated with NVP-BEZ235 and PP242, whereas only potent inhibition of mTOR activity was induced in Rapamycin-treated cells. In considering the overactivation of c-Jun and IκB-α in human renal tumor tissue, we next investigated the role of JNK and IKK pathways in the response of RCC cells to these compounds. First of all, transforming growth factor β activated kinase 1 (TAK1)-dependent activation of JNK/ (activator protein-1) AP-1 axis in RCC cells was proved by the repression of AP-1 activity with TAK1 or JNK inhibitor. Second, the profound inhibition of TAK1/JNK/AP-1 pathway was demonstrated in RCC cells treated with NVP-BEZ235 or PP242 but not Rapamycin, which is manifested as a reduction in activity of TAK1, c-Jun and AP-1. Meanwhile, subsequent to TAK1 inactivation, the activation of IκB-α was also reduced by NVP-BEZ235 and PP242. Likewise, in vivo, treatment with NVP-BEZ235 and PP242 suppressed the growth of xenografts generated from 786-0 and A498 cells, along with decreased expression of phospho-TAK1, phospho-c-Jun, and phospho-IκB-α. In contrast, Rapamycin elicited no significant inhibitory effects on tumor growth and phosphorylation of TAK1, c-Jun and IκB-α. We conclude that besides PI3K/Akt/mTOR signaling, NVP-BEZ235, and PP242 simultaneously target TAK1-dependent pathways in RCC cells. Notably, these effects were more marked in the presence of NVP-BEZ235 than PP242, indicating the potential application of NVP-BEZ235 in combination therapy for RCC.
History
References
- https://doi.org//10.1007/s10495-018-1490-7
- https://doi.org//10.3892/or.2018.6457
- https://doi.org//10.1016/j.semcancer.2019.07.009
- https://doi.org//10.1158/0008-5472.CAN-12-2362
- https://doi.org//10.1096/fj.201802805RR
- https://doi.org//10.1016/j.ccell.2017.02.004
- https://doi.org//10.3322/caac.21492
- https://doi.org//10.1016/j.canlet.2017.07.021
- https://doi.org//10.1016/j.tips.2014.11.004
- https://doi.org//10.1007/s10549-018-4697-y
- https://doi.org//10.1016/j.jgg.2015.03.003
- https://doi.org//10.1016/j.freeradbiomed.2018.09.043
- https://doi.org//10.1007/s12640-017-9837-3
- https://doi.org//10.3390/ijms18102195
- https://doi.org//10.1007/s10787-017-0336-116
- https://doi.org//10.1002/bies.202100093
- https://doi.org//10.1039/c9bm00653b
- https://doi.org//10.1038/nrurol.2016.260
- https://doi.org//10.1016/j.juro.2012.11.010
- https://doi.org//10.1146/annurev-med-062913-051343
- https://doi.org//10.1186/s13045-019-0720-y
- https://doi.org//10.1186/s12964-017-0174-1
- https://doi.org//10.1093/jjco/hyz013
- https://doi.org//10.3390/cells9112470
- https://doi.org//10.1080/2090598X.2019.1590516
- https://doi.org//10.3389/fonc.2014.00064
- https://doi.org//10.1016/j.phrs.2019.03.006
- https://doi.org//10.1016/j.cell.2017.03.03510.1016/j.cell.2017.02.004
- https://doi.org//10.1182/blood.2020009404
- https://doi.org//10.3389/fpls.2016.01746
- https://doi.org//10.1172/JCI86120
- https://doi.org//10.1007/s11605-015-2767-6
- https://doi.org//10.1038/nature12122
- https://doi.org//10.1186/s12943-019-0954-x
- https://doi.org//10.1073/pnas.2017152117
- https://doi.org//10.3892/mmr.2015.4528
- https://doi.org//10.3892/ol.2020.12189